DFB Soria LLC is an affiliate of NanOlogy and is owned and operated by DFB Pharmaceuticals.  Soria entered into an exclusive worldwide license with CritiTech for use of its submicron particle production technology in certain fields outside of oncology including dermatology.
The key scientific advance in our submicron particle production technology is the patented use of sonic energy and super critical fluid carbon dioxide to reduce unprocessed paclitaxel API crystals by up to 400 times into stable, naked NanoPac® (nanoparticle paclitaxel) with exponentially increased surface area and unique geometry. NanoPac is then suspended in a stable, patented, anhydrous base identified as SOR007 that was designed to optimize epithelial and dermal penetration. Learn more about the Technology.
SOR007 (uncoated nanoparticle paclitaxel) Ointment has demonstrated dermal penetration in vitro, completed an in vivo dermal toxicity study, and shown negligible systemic absorption along with no adverse systemic effects in a phase 1 psoriasis clinical trial. SOR007 is under clinical investigation for actinic keratosis and cutaneous metastases (via license to NanOlogy). It is also under nonclinical evaluation for cervical intraepithelial neoplasia.
Clinical Programs

Current Clinical Trials of SOR007 (uncoated nanoparticle paclitaxel) Ointment

Phase 2 Trial:  Open-label, dose-rising study evaluating SOR007 (uncoated nanoparticle paclitaxel) Ointment for the treatment of cutaneous metastases from non-melanoma cancer.  (NanOlogy program.)
Phase 2 Trial:  Randomized, double-blind, dose rising study to determine the safety, tolerability, and preliminary efficacy of four concentrations of SOR007 (uncoated nanoparticle paclitaxel) Ointment compared to ointment vehicle applied to actinic keratosis (AK) lesions.  (Soria program.)
See the complete NanOlogy & Soria Pipeline.